Summary
- Profile Type
- Technology offer
- POD Reference
- TOKR20240827004
- Term of Validity
- 27 August 2024 - 27 August 2025
- Company's Country
- South Korea
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- ORGANOISCIENCES, a leading clinical-stage biotech company, develops organoid-based therapeutics using their ATORM platform for treating inflammatory bowel diseases and their ODISEI platform for precise oncology drug discovery. These innovations offer groundbreaking treatment options and promise significant advancements in regenerative and precision medicine.
- Full Description
-
Founded in 2018, this South Korea-based biotech company focuses on advancing human health by developing organoid-based medical technologies. These technologies aim to address organ damage and shortages, positioning the company as a leader in the biotech industry. The company specializes in two primary platforms: ATORM (Adult Tissue-derived Organoid-based Regenerative Medicine) and ODISEI (Organoid-based Discovery platform for Innovative Screening, Evaluation, and Identification).
Organizational Structure and Activity Field
The company operates as a biotech firm focused on organoid technology, particularly in regenerative medicine and drug discovery. The ATORM platform is designed to regenerate damaged tissues using organoids derived from adult tissue-specific stem cells. This platform is in the clinical trial phase, with multiple pipelines addressing conditions like refractory ulcers and salivary gland damage. The company employs advanced methods, such as endoscopic biopsies and transplants, to deliver these therapies effectively.
On the other hand, the ODISEI platform focuses on oncology drug discovery. This platform leverages patient-derived tumor organoids and immune cells to create a highly accurate in vitro model for evaluating immunotherapy drugs. The ODISEI platform overcomes traditional limitations by ensuring proper matching of Major Histocompatibility Complex (MHC) and T-cell receptors (TCR), thereby enabling more precise testing of immune checkpoint inhibitors.
Expertise and Know-How for Potential Partners
The company is open to sharing its specialized knowledge and expertise with potential partners. This includes insights into the GMP process for organoid therapeutic development, the use of organoids in regenerative medicine, and the application of organoid technology in personalized medicine and drug discovery. The company also offers its proprietary platforms for collaborative research, allowing partners to explore new therapeutic avenues and drug discovery methods.
Desired Partner Types and Collaboration Rationale
The company seeks partnerships with organizations involved in clinical research, pharmaceutical development, and regenerative medicine. Specifically, they are interested in collaborating with entities that have expertise in inflammatory diseases, oncology, and immunotherapy.
1. Rationale for Partner Selection:
• The company’s ATORM platform targets regenerative medicine, making collaboration with clinical research institutions and hospitals essential for advancing their clinical trials. In the case of the ODISEI platform, partnerships with pharmaceutical companies and research institutions focusing on oncology and immunotherapy are critical. These partnerships would help validate and scale their platforms, enabling the development of new therapies.
2. Collaboration Plan:
• Clinical Trials: For the ATORM platform, the company plans to collaborate with hospitals and research centers to conduct Phase 1 clinical trials. These collaborations will involve sharing data, providing training on the use of the platform, and jointly developing treatment protocols.
• Drug Discovery: For the ODISEI platform, the company aims to partner with pharmaceutical firms to co-develop new oncology drugs. The collaboration would involve utilizing the ODISEI platform to screen drug candidates and validate their efficacy in a highly controlled - Advantages and Innovations
-
The company’s ATORM and ODISEI platforms represent key innovations in regenerative medicine and oncology drug discovery, offering distinct advantages over existing technologies.
ATORM’s Innovation and Competitive Advantage:
The ATORM platform fundamentally changes the treatment of chronic and degenerative diseases by regenerating damaged tissues using organoids derived from adult tissue-specific stem cells. Unlike conventional therapies that manage symptoms, ATORM directly addresses the underlying causes, offering potentially long-lasting and effective treatments. Its use of autologous organoids reduces the risk of immune rejection, enhancing safety and efficacy. ATORM’s ability to treat conditions like radiation-induced xerostomia, where no other viable treatments exist, positions it as a breakthrough in regenerative medicine. If successful, ATORM could set a new standard in this field.
ODISEI’s Innovation and Competitive Advantage:
The ODISEI platform excels in oncology drug discovery by accurately replicating the tumor microenvironment (TME) using patient-derived tumor organoids and various immune cells. This precision allows for a more reliable assessment of immunotherapy drugs, addressing the challenge of tumor heterogeneity. ODISEI’s extensive organoid library, including over 20 cancer types, enables high customization, making it a valuable tool for pharmaceutical companies. Its success in collaborations highlights its reliability in developing new cancer treatments, potentially reducing the risk of late-stage drug development failures and accelerating the delivery of effective therapies.
Both platforms offer groundbreaking innovations that strengthen the company’s competitive position and promise significant improvements in patient outcomes. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 8: Decent Work and Economic Growth
- Goal 9: Industry, Innovation and Infrastructure
Partner Sought
- Expected Role of a Partner
-
For the ODISEI platform, the company seeks partners who are engaged in the discovery and development of new therapeutic agents, including both oncological and non-oncological drugs. The ideal partner would be a pharmaceutical or biotech company focused on cutting-edge drug discovery, efficacy evaluation, and the development of innovative compounds. The partner is expected to:
1. Collaborative Drug Discovery:
• Work with the company to utilize the ODISEI platform for the discovery of new drugs, leveraging its ability to accurately replicate the tumor microenvironment (TME) and other complex biological systems. This collaboration would focus not only on oncology drugs but also on other therapeutic areas, such as microbiome-related treatments and cosmeceuticals.
• Provide their own drug candidates or compounds for testing within the ODISEI platform, using the company’s advanced organoid models to assess efficacy, safety, and potential therapeutic benefits.
2. Efficacy Evaluation and Customization:
• Partner with the company to evaluate the efficacy of new compounds, using the ODISEI platform’s ability to co-culture patient-derived tumor organoids with immune cells. This precise evaluation is crucial for developing effective immunotherapies and other targeted treatments.
• Collaborate on the customization of the ODISEI platform to meet specific research needs, such as tailoring the platform to study specific types of cancer or other diseases. This includes using the platform to model different patient populations and their unique responses to treatment.
3. Exploration of Non-Oncological Applications:
• Engage in the exploration of non-oncological applications of the ODISEI platform, including the discovery of new microbiome therapies and cosmetic products. The platform’s versatility in modeling various biological environments makes it a valuable tool for testing a wide range of compounds beyond oncology.
• Work on the development of novel cosmeceuticals or microbiome-related treatments, utilizing the ODISEI platform to ensure their safety and efficacy before market introduction.
4. Market Introduction and Expansion:
• Assist in the commercialization of products developed using the ODISEI platform, particularly in bringing innovative therapies to market. This includes supporting regulatory approvals, market strategy development, and the scaling of production for global distribution.
• Collaborate on expanding the use of the ODISEI platform across different therapeutic areas, helping to identify and capitalize on new market opportunities in both oncology and non-oncology sectors.
Conclusion:
The company is seeking partners who can not only collaborate in the development of its ATORM and ODISEI platforms but also play a critical role in bringing these next-generation therapies and drug discovery tools to the global market. For ATORM, the ideal partner would be deeply involved in the co-development and global commercialization of regenerative therapies, ensuring that these innovative treatments reach patients in need around the world. For ODISEI, the partner would focus on leveraging the platform’s advanced capabilities to discover and develop new drugs, including both cancer therapies and non-oncological products such as microbiome treatments and cosmeceuticals. Through these strategic partnerships, the company aims to drive innovation and improve patient outcomes globally.⬤ - Type and Size of Partner
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Investment agreement
Dissemination
- Technology keywords
- 06001008 - Environmental Medicine, Social Medicine, Sports Medicine
- Market keywords
- 05005022 - Other clinical medicine
- Targeted countries
- All countries